Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer

ABSTRACT: This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced colorectal cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for colorectal cancer.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms,Advanced Colorectal Cancer

PROVIDER: 2272861 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR